Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs), such as anti–CTLA-4 and anti–PD-1 antibodies, are effective against several malignancies. They are associated with gastrointestinal immune-related adverse events (GI-IrAEs), which may be severe and lead to ICI discontinuation. We assessed the risk of evolution of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2019-01, Vol.106, p.106-114
Hauptverfasser:	de Malet, Alice, Antoni, Guillemette, Collins, Michael, Soularue, Emilie, Marthey, Lysiane, Vaysse, Thibaut, Coutzac, Clelia, Chaput, Nathalie, Mateus, Christine, Robert, Caroline, Carbonnel, Franck
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenal Cortex Hormones - therapeutic use Adult Aged Aged, 80 and over Anti-Inflammatory Agents - therapeutic use Antibodies Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Cancer Chronic Disease Confidence intervals CTLA-4 protein Drug Administration Schedule Drug toxicity Enterocolitis - chemically induced Enterocolitis - diagnosis Enterocolitis - drug therapy Enterocolitis - immunology Evolution Female Gastritis - chemically induced Gastritis - diagnosis Gastritis - drug therapy Gastritis - immunology Gastrointestinal diseases Gastrointestinal toxicity Humans Immune checkpoint inhibitors Immune system Immunoglobulins Immunotherapy Inhibitors Life Sciences Male Middle Aged Molecular Targeted Therapy - adverse effects Patients PD-1 protein Rank tests Recurrence Reintroduction Retrospective Studies Risk Assessment Risk Factors Side effects Signs and symptoms Time Factors Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!